Insulin Toujeo® — a Novel Basal Long-Acting Insulin Formulation. Part 1. Pharmacokinetic and Pharmacodynamic Aspects

V.V. Poltorak, N.A. Kravchun, M.Yu. Gorshunska

Abstract


This review, consisting of two parts, considers a new formulation of insulin glargine (rDNA origin) in the form of injections 300 U/ml (Gla-300, Toujeo®). Gla-300 is a next generation basal insulin with a novel formulation of insulin glargin delivering the same amount of insulin, as glargine-100 (Gla-100, Lantus®) in 1/3 volume. Following the subcutaneous injection, pharmacokinetic and pharmacodynamic profiles of Gla-300 are more constant and prolonged (beyond 24 hours) compared with Gla-100 due to a more gradual and extended release of glargine from subcutaneous depot (Gla-300 forms a more compact subcutaneous depot with reduced surface area compared to Gla-100). The clinical efficacy and safety of Gla-300 in patients with type 1 and type 2 diabetes mellitus are discussed with an emphasis on recently released data from EDITION (the phase 3a) clinical trials. Gla-300 showed comparable glycaemic control and similar safety profile with lower incidence of hypoglycaemia events compared with Gla-100. Gla-300 provided flexible dosing of insulin (24 ± 3 h or morning vs evening) and was associated with less body weight gain.


Keywords


diabetes mellitus; glycated hemoglobin; hypoglycaemia; glargine; insulin; Gla-100 (Lantus®); Gla-300 (Toujeo®)

References


Ahsen B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Healht Risk Man 2013;9:155-163 doi: 10.2147/VHRM.S33934

American Diabetes Association Standarts of medical care in diabetes. Diabetes Care 2014;(Suppl 37):S14 –S80 doi:10.2337/dc14-S014

Andrews MA, O’Malley PG, Diabetes overtreatment in eldery individuals: risky business in need of better management. JAMA 2014;311:2326-2327. doi:10.1001/jama.2014.4563.

Approval package for application number NDA 21-081/S-024, 2007. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2007/0210810 rig1s024.pdf

Arnolds S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract 2010;64:1415-1424. doi:10.1111/j.1742-1241.2010.02470.x.

Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014;383:69-82. doi: 10.1016/S0140-6736(13)60591-7.

Atkinson MA, George S, Eisenbarth GS. 1947-2012. Diabetologia 2013;56:435-438. doi:10.1007/s00125-013-2833-0.

Atkinson MA, Herrath M., Powers AC, Clare-Salzer M. Current concepts of the pathogenesis of type 1 diabetes - considerations for attempts to prevent and reverse the disease. Diabetes Care 2015;38:979-988 doi 10.2337/dc15-0144

A Trial Comparing Cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events (DEVOTE). ClinicalTrials.gov; US National Institutes of Health. Available from : http//www.clinicaltrial.gov/ct2/show/NTC01959529?term-devote+degludec&rank=1.

Barlocco D. Insulin detemir. Novo Nordisk. Curr Opin Investig Drugs 2003;4:449-454. PMID: 12808886

Barnett AH. Insulin glargine in the treatment of type 1 and type 2 diabetes. Vask Health Risk Manag 2006;2:59-67. PMID: 17319470

Becker RHA, Hahn AD, Boderke P et al. 2011. European Patent Applicator Long-acting formulations of insulins. European Patent Office (Application No. 11166415.7). Available from https://data.epo.org.

Becker RHA, Nowotny I, Teichert L, Bergmann K, Kapitza C. Low within- and between-day variability in exposure to new insulin glarginc 300 U.ml-1. 74th Scientific sessions of ADA, San Francisco, USA, 13-17 June 2014, Abstract 892-P doi: 10.1111/dom.12416.

Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 units-mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units-ml-1. Diabetes Care 2015;38:637-643. doi: 10.2337/dc14-0006.

Bergenstal R, Bailey T, Robard D, Guo H, Muehlen-Bartmer I, Ahmann AJ. Insulin glargine 300 U/ml vs 100 U/ml: glucose profiles of morning vs evening injections in adults with T1DM measured with continuous glucose monitoring (CGM). Diabetes Technol Ther 2015;17:A16-17. doi: 10.1089/dia.2010.0251.

Bergenstal R.M. et al, Insulin glargine 300 U/ml vs 100 U/ml: glucose profiles of morning vs evening injections in adults with T1DM measured with continuous glucose monitoring (CGM). 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15-19 September 2014, Abstract 949.

Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ. A randomized controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147. doi:10.2337/dc12-0060.

Bolli GB, Owens DR Insulin glargine. Lancet. 2000;356:443-445.

Bolli GB, Andreoli AM, Lucidi P. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era Diabetes Technol Ther 2011;13 (Suppl. 1):S43-52. doi:10.1089/dia.2011.0039.

Bolli GB, Hahn AD, Schmidt R, Eisenblaetter T, Dahmen R, Heise T, Becker RH, Bolli GB, Hahn AD, Schmidt R. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care 2012;35:2626-2630. doi: 10.2337/dc12-0270.

Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/ml: glycaemic control and hypoglycaemia in insulin-naive people with type 2 diabetes mellitus (EDITION 3). 74th Scientific sessions of ADA, San Francisco, USA, 13-17 June 2014, Abstract 947.

Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD. New insulin Glargine 300 U/ml: glycaemic control and hypoglycaemia in insulin naïve people with T2DM (EDITION 3). 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15-19 September 2014, Abstract 947.

Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD; on behalf of the EDITION 3 study investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015;17:386-394. doi: 10.1111/dom.12438.

Bolli GB, De Vries JH. New long-acting insulin analogs: from clamp studies to clinical practice. Diabetes Care 2015;38:541-543. doi: 10.2337/dc14-2314

Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med 2012;124-132. doi: 10.3810/pgm.2012.01.2525.

Butler AE, Galasso R, Meier JJ, Basu R, Rizza RA, Butler PC. Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis. Diabetologia 2007;50:2323-2331. doi: 10.1007/s00125-007-0794-x

Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007;57:455-460. PMID: 17550670

Camprioni M, Tofolo G, Basu R, Rizza RA, Cobelli C. Minimal model assessment of hepatic insulin extraction during an oral test from standard insulin kinetic parameters. Am J Physiol Endocrinol Metab 2009;297:E941-E948. doi: 10.1152/ajpendo.90842.2008.

Chapman TM, Perry CM. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2004;64:2577-2595.

Dahmen R, Bergmann K, Lehmann A, Tillner J, Jax T, Heise T, Becker RHA. New insulin glargine U300 formulation events and prolongs steady state PK and PD profiles during euglycemic clamp in patients with type 1 diabetes (T1DM). Diabetes 2013;62(Suppl 1):A29.

Data on file-Real-World Data On Hypos following Basal Insulin Initiation (Value@Access team)

Davies M. The reality of glycemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord 2004;28(Suppl. 2):S14–22. doi:10.1038/sj.ijo.0802745.

Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. Diabet Med 2013;30:512-524. doi:10.1111/dme.12128.

Deiss D, Kordonouri O, Hartmann R, Hopfenmüller W, Lüpke K, Danne T. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes. Pediatr Diabetes 2007;8:157-162. PMID: 17550426

Dorland’s illustrated medical dictionary, edition 28, W.B. Saunders company.

Eaton RP, Allen RC, Shade DS, Standefer JC. «Normal» insulin secretion: the goal of artifical insulin delivery systems? Diabetes Care 1980;3:270-273. PMID: 6993139

Eaton RP, Allen RC, Shade DS. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J Clin Endocrinol Metab 1983;56:1294-1300.

Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 2011;8:677-684. doi: 10.1111/j.1463-1326.2011.01395.x.

Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insuline glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases. Diabetes Care 2013;36:294-301. doi: 10.2337/dc12-0506.

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin Degludec an ultra-longating basal insulin, versus insulin glargine in basal bolus treatment with mealtime insulin apart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomized open-label, treat-to-target non-inferiority trial Lancet. 2012;379: 1498-507. doi:10.1016/S0140-6736(12)60205-0.

Gerstein HC, Bosch J, Dagenais GR, ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328. doi:10.1056/NEJMoa1203858.

Gough SC, Harris S, Woo V, Davies M. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes Metab 2013;15:301-309. doi: 10.1111/dom.12052.

Goykhman S, Drincic A, Desmangles JC, Rendell M. Insulin glargine a review 8 years after its introduction. Expert Opin Pharmacother 2009;10:705-718. doi:10.1517/14656560902775677.

Grimaldi-Bensouda L, Cameron D, Marty M, Barnett AH, Penault-Llorca F, Pollak M, Charbonnel B, Riddle M, Mignot L, Boivin JF, Khachatryan A, Rossignol M, Bénichou J, Alpérovitch A, Abenhaim L; ISICA Group. Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care 2014;37:134-143. doi: 10.2337/dc13-0695.

Gualandi-Signorini AM, Giorgi G. Insulin formulations - a review. Eur Rev Med Pharmacol Sci 2001;5:73-83. PMID: 12004916

Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944-950. doi: 10.1111/j.1463-1326.2012.01638.x.

Heller S, Koenen C, Bode B. Comparison of insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes a 52-week, multinational, randomized open-label, parallel group, treat-to-target, noninferiority trial. Clin Ther 2009;31:2086-2097. doi:10.1016/j.clinthera.2009.10.006.

Henricksen JH, Tronier B, Bülow JB. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. Metabolism 1987;36:463-468. PMID: 3553849

Hilgenfeld R, Seipke G, Berchold H, Owens DR. The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs 2014;74:911-927. doi:10.1007/s40265-014-0226-4.

Hirsch IB, Bergenstal RM, Parkin ChG, Wright E, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabet 2005;23:78-86.

Hollander P, Cooper J, Bregnhoi J, Pedersen CB. A 52-week, multinational open-label parallel-group noninferiority treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-1987. doi:10.1016/j.clinthera.2008.11.001.

Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK. 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736–1747. doi:10.1056/NEJMoa0905479.

Home PD, Bergenstal RM, Riddle MC, Ziemen M, Rojeski M, Espinasse M, Bolli GB. Glycaemic control and hypoglycaemia with new insulin Glargine 300 U/mL in people with type 1 diabetes (EDITION 4). Diabetologia 2014;57(Suppl. 1): S69. doi:10.1007/s00125-013-3012-z

Home PD, Bergenstal RM, Riddle MC, Ziemen M, Rojeski M, Espinasse M, Bolli GB. Glycemic control and hypoglycemia with new insulin glargine 300U/ml in people with T1DM (EDITION 4). 74th Scientific sessions of ADA, San Francisco, USA, 13-17 June 2014, Abstract 80-LB.

Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M., Espinasse M, Riddle MC. New insulin glargine 300Units/ml versus glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015. doi:10.2337/dc15-0249/-/DC1.

Hopkins D. Exercise-induced and other daytime hypoglycemic events in patients with diabetes: prevention and treatment. Diabetes Res Clin Pract 2004;65(Suppl. 1):S35-S39.

Horvath K, Jeitler K,Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochane Database Syst Rev 2007; CD005613.

Iglesias P, Diez JJ. Insulin therapy in renal disease. Diabetes Obes Metab 2008;10:811-823.

International Diabetes Federation. Diabetes Atlas, 6th edition, Brussels, Belgium: International Diabetes Federation, 2013.

Investigators OT, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycaemia. N Engl J Med 2012;367:319-328. doi:10.1056/NEJMoa1203858.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2015;38:140-149. doi:10.2337/dc14-2441.

Ishii H, Iwamoto Y, Tajima N. An Exploration of Barriers to Insulin Initiation for Physicians in Japan: Findings from the Diabetes Attitudes, Wishes and Needs (DAWN) JAPAN Study. PLoS One 2012;7:e36361. doi: 10.1371/journal.pone.0036361.

Jax J, Heise T, Dahmen R. New insulin glargine formulation has a flat and prolonged steady state profile in subjects with type 1 diabetes. Diabetologia 2013;56:A1029.

Jeandidier N, Riddle MC, Bolli GB, Bergenstal RM, Ziemen M, Muehlen-Bartner I, Wardecki M, Vinet L, Yki-Jarvinen H. New insulin Glargine 300 U/ml: efficacy and safety of flexible vs fixed dosing intervals in people with 2 diabetes mellitus. 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15-19 September 2014, Abstract 961.

Jinnouchi H, Koyama M, Amano A, Takahashi Y, Yoshida A, Hieshima K, Sugiyama S, Krinami N, Jinnouchi T, Becker R. Continuous Glucose monitoring during basal-bolus therapy using Glargine 300 U ml-1 and Glargine 100 U ml-1 in Japanese People with Type 1 Diabetes Mellitus: A Crossover pilot study. Diabetes Ther 2015. doi 10.1007/s13300-015-0115-1.

Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract 2000;50:161-167. doi:10.1016/S0168-8227(00)00196-0.

Kuerzel GU, Shukla U, Scholtz HE, Pretorius SG, Wessels DH, Venter C, Potgieter MA, Lang AM, Koose T, Bernhardt E. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003;19:34-40. PMID: 12661778

Kuricova K, Pacal L, Kankova K. Hypoglycemia Increases Expression of Several Genes Upregulated by Hyperglycemia. 74th Scientific sessions of ADA, San Francisco, USA, 13-17 June 2014, Abstract 401-P.

Lambert PC, Sutton AJ, Abrams KP, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 2002;55:86-94. doi: 10.1016/S0895-4356(01)00414-0

Lamy A, Tong W, Jung H, Gafni A, Singh K, Tyrwhitt J, Yusuf S, Gerstein HC, ORIGIN Investigators. Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. J Diabetes Complications 2014;28:553-558. doi:10.1016/j.jdiacomp.2014.02.012

Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD. DARTS/MEMO Collaboration Leese GP,Wang J, Broomhall J. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-1180. doi: 10.2337/diacare.26.4.1176.

Leiter LA, Yale J-F, Chiasson J-L et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186–192.

Lucidi P, Porcellati F, Candeloro P, Cioli P, Andreoli AM, Marzotti S, Schmidt R, Bolli GB, Fanelli CG. Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study. Nutr Metab Cardiovasc Dis 2014;24:709-716. doi:10.1016/j.numecd.2014.02.008.

Mannucci E, Giannini S, Dicembrini I. Cardiovascular effects of basal insulins. Drug Healthc Patient Saf 2015;7:113-120. doi: 10.2147/DHPS.S43300

Markussen J, Diers I, Hougaard P, Langkjaer L, Norris K, Snel L, Sørensen AR, Sørensen E, Voigt HO. Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. Protein Eng 1988;2:157-166. doi:10.1093/protein/2.2.157

Martens GA, Van de Casteele M. Glycemic control of apoptosis in the pancreatic beta cell: danger of extremes? Antioxid Redox Sygnal 2007;9:309-317. PMID: 17184175

Matsuhisa M. Koyama M, Cheng X, Shimizu S, Hirose T. New insulin Glargine 300 U/ml: glycaemic control and hypoglycaemia in Japanese people with T1DM (EDITION JP 1). 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15-19 September 2014, Abstract 975.

Matsuhisa M, Koyama M, Cheng X, Shimizu S, Hirose T. EDITION JP 1 Study Group. New insulin glargine 300 U/mL: glycemic control and hypoglycemia in Japanese people with T1DM (EDIT1C JP I). 74th Scientific sessions of ADA, San Francisco, USA, 13-17 June 2014, Abstract 88-LB.

Matsuhisa M, Koyama M, Cheng X, Sumi M, Hirose T. Sustained glycemic control and less nocturnal hypoglycemia with new insulin glargine 300 U/mL compared with glargine 100 U/mL over 12 months in Japanese people with T1DM (EDITION JP 1) on behalf of the EDITION JP 1 study group. 75th Scientific sessions of ADA, Boston, USA, 5-9 June 2015, Abstract 987-P.

Meier J.J. Beta cell mass in diabetes: a realistic therapeutic target? Diabetоlogia 2008;51: 703-713. doi: 10.1007/s00125-008-0936-9.

Mellbin LG, Ryden L, Riddle MC, Probstfield J, Rosenstock J, Díaz R, Yusuf S, Gerstein HC.Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013;34:3137-3144. doi: 10.1093/eurheartj/eht332.

Monami M, Adalsteinsson JE, Desireri CM, Ragghianti B, Dicembrini I, Mannucci E. Fasting and post-prandial glucose and diabetic complication. A meta-analysis. Nurt Metab Cardiovasc Dis 2013;23:591-598. doi: 10.1016/j.numecd.2013.03.007.

Monti LD, Poma R, Caumo A, Stefani I, Picardi A, Sandoli EP, Zoltobrocki M, Micossi P, Pozza G. Intravenous infusion of diarginylinsulin, an insulin analogue: effects on glucose turnover and lipid levels in insulin-treated type 2 diabetic patients. Metabolism 1992;41:540-544. PMID: 1588835

Mullins P, Sharplin P,Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral Hagedorn insulin in type 1 and 2 diabetes mellitus. Clin Ther 2007; 29:1607-1619. PMID: 17919543

Nieuwesteeg A, Pouwer F, van der Kamp R, van Bakel H. Quality of life of children with type 1 diabetes: a systematic review. Curr Diabetes Rev 2012;8:434-443. doi:10.2174/157339912803529850.

Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011;378:169-181. doi: 10.1016/S0140-6736(11)60614-4.

Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011; 13 (Suppl. 1):S5-14. doi:10.1089/dia.2011.0068.

Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res Rev 2014;30;104-119. doi:10.1002/dmrr.2469.

Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29:682–689. doi: 10.1111/j.1464-5491.2012.03605.x.

Pieber TR, Treichel HC, Hompresch B, Philotheou A, Mordhorst L, Gall MA, Robertson LI. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin. Diabet Med 2007;24:635-642. doi:10.1111/j.1464-5491.2007.02113.x.

Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Pshycological insulin resistance in patients with type 2 diabetes: the score of the problem. Diabetes Care 2005; 28:2543-2545.

Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2011;13:1008-1019. doi: 10.1111/j.1463-1326.2011.01433.x.

Porcellati F,. Rossetti P, Busciantella RN, Marzotti S, Lucidi P, Luzio S, Owens DR, Bolli GB, Fanelli CG. Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007;30:2447-2452. doi:10.2337/dc07-0002

Porcellati F, Lucidi P, Cioli P, Candeloro P, Marinelli Andreoli A, Marzotti S, Ambrogi M, Bolli GB, Fanelli CG. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. Diabetes Care 2015;38:503-512. doi:10.2337/dc14-0649.

Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009;25:542-548. doi:10.1002/dmrr.989.

Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA, Less hypoglycemia with insulin Glargine in intensive insulin therapy for type 1 diabetes. US Study Group of insulin Glargine in type 1 diabetes. Diabetes Care 2000;23:639-643. doi: 10.2337/diacare.23.5.639.

Ricci C, Pastukh V, Mozafarri M, Shaffer SW. Insulin withdrawal induces apoptosis via a free radical mediated mechanism. Can J Physiol Pharmacol 2007;85:455-464. doi:10.1139/Y07-02

Riddle MC, Bolli GB, Yki-Jarvinen H, Ziemen M, Muehlen-Bartmer I, Cissokho S, Home PD. Sustained glycemic control and hypoglycemia with new insulin glargine 300 U/mL compared with 100 U/ml: one-year results in people with T2DM using basal + mealtime insulin (EDITION 1). 74th Scientific sessions of ADA, San Francisco, USA, 13-17 June 2014, Abstract 81-LB.

Riddle MC, Bolli GB., Home PD et al. New insulin glargine 300 U/ml: efficacy and safety of adaptable vs fixed dosing intervals in people with T2DM. 74th Scientific sessions of ADA, San Francisco, USA, 13-17 June 2014, Abstract 919-P.

Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37:2755-2762. doi:10.2337/dc14-0991.

Ritzel R, Roussel R, Bolli G, Vinet L, Yki-Jarvinen H. New insulin Glargine 300 U/ml: glycaemic control and hypoglycaemia in a meta-analysis of phase 3a EDITION Clinical trials in people with T2DM. 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15-19 September 2014, Abstract 963.

Ritzel R, Roussel R, Bolli G, Vinet L, Yki-Jarvinen H. New insulin glargine 300 U/ml: glycaemic control and hypoglycaemia in a meta-analysis of phase 3a EDITION clinical trials in people with T2DM. 74th Scientific sessions of ADA, San Francisco, USA, 13-17 June 2014, Abstract 90-LB.

Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, Yki-Jarvinen H. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015;9:859-867. doi: 10.1111/dom.12485

Ritzel R, Roussel R, Giaccari A, Vora JP, Grisoni M-L, Brulle-Wohlhueter C, Glezer S, Yki-Jarvinen H.. Glycemic control and hypoglycemia with insulin glargine 300 U/mL (Gla-300) vs glargine 100 U/mL (Gla-100) in type 2 diabetes (T2DM) in a patient-level meta-analysis of 1-year phase 3a EDITION studies. 75th Scientific sessions of ADA, Boston, USA, 5-9 June 2015, Abstract 1030-P.

Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-955. doi:10.2337/diacare.28.4.950

Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomized, 52-week, treat-to-target trial comparing insulin detemir with type 2 diabetes. Diabetologia 2008;51:408-416. doi:10.1007/s00125-007-0911-x.

Roussel R, d’Emden MC, Fisher M, Ampudia-Blasco FJ, Stella P, Grisoni M-L, Cali AMG, Wysham CH. Switching from twice-daily basal insulin to once-daily new insulin glargine 300 U/mL (Gla-300): an analysis in people with T2DM (EDITION 1 and 2), 75th Scientific sessions of ADA, Boston, USA, 5-9 June 2015, Abstract 1021-P.

Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007; 24:1412-1418. doi: 10.1111/j.1464-5491.2007.02279.x

Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC Guidelines on diabetes, prediabetes, and cardiovascular disease developed in collaboration with EASD. Eur Heart J 2013;34;3035-3087. doi:10.1093/eurheartj/eht108.

Sanofi. Clinical study results. Phase I in Japanese patients with type 1 diabetes mellitus. 2013. Available from: http://cn.sanofi.com/img/content/study/pdf2777-summary.pdf.

Schisano B, Tripathi G, McGee K, McTernan PG, Ceriello A. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 2011;54:1219-1226. doi: 10.1007/s00125-011-2049-0.

Shiramoto M, Eto T, Irie S, Fukuzaki A, Teichert L, Tillner J, Takahashi Y, Koyama M, Dahmen R, Heise T, Becker RH. Single-dose insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015;17:254-260. doi: 10.1111/dom.12415.

Shiramoto M, Eto T, Watanabe A, et al. Single dose of new insulin glargine Gla-300 formulation has a flatter and prolonged PK/PD profile than Gla-100 in Japanese subjects with type 1 diabetes. Diabetologia 2013;56:A1031

Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16:344-350. doi: 10.1111/dom.12222.

Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther 2011;13(Suppl. 1):S103-108 doi:10.1089/dia.2010.0251.

Sommerfled MR, Muller G, Tschank G, Seipke G, Habermann P, Kurrle R, Tennagels N. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One 2010. – Vol. 5. – P.e9540. doi: 10.1371/journal.pone.0009540.

Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RHA. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014;16:873-876. doi:10.1111/dom.12283.

Sutton G, Minguet J, Ferrero C, Bramlage P. U300, A novel long-acting insulin formulation. Expert Opin Biol Ther 2014; 14:1849-1860. doi: 10.1517/14712598.2014.970633

Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, Snoek FJ, Devries JH, Hoekstra JB, Holleman F. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33:1176-1178. doi:10.2337/dc09-2294.

Teramukai S, Matsuyama Y, Mizuno S, Sakamoto J. Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect. Jpn J Clin Oncol 2004; 34:717-721. doi:10.1093/jjco/hyh138.

Terauchi Y, Koyama M, Cheng X, Shimizu S, Hirose T, on behalf of the EDITION JP 2 study group. Glycemic control and hypoglycaemia in Japanese people with T2DM receiving New insulin Glargine 300 U/ml in combination with OADs (EDITION JP 2). 50th Annual meeting of the European Association for the Study Diabetes, Vienna, Austria, 15-19 September 2014, Abstract 976.

Terauchi Y, Koyama M, Cheng X, Shimizu S, Hirose T, on behalf of the EDITION JP2 STUDY GROUP. Glycaemic control and hypoglycaemia in Japanese people with T2DM receiving new insulin glargine 300 U/ml in combination with OADSs (EDITION JP 2) 74th Scientific sessions of ADA, San Francisco, USA, 13-17 June 2014, Abstract 94-LB.

Tibaldi J.M. Evolution of insulin development: focus on key parameters. Adv Ther 2012;29:590-619. doi: 10.1007/s12325-012-0034-8.

Tillner J, Bergmann K, Teichert L, Dahmen R, Heise T, Becker RHA. Euglycemic clamp profile of new insulin glargine U300 formulation in patients with type 1 diabetes (T1DM) is different from glargine U100. Diabetes 2013;62(Suppl. 1):A234.

Toujeo (U300)-ePress Pack. [Electronic resourse] Value and access team. Data on file – Real-World on hypos following basal insulin initiation.

Tschope D, Bramlage P, Binz C, Krekler M, Deeg E, Gitt A. Incidence and predictors of hypoglycaemia in type 2 diabetes – an analysis of the prospective DiaRegis registry. BMC Endocr Disord 2012;12:23. doi: 10.1186/1472-6823-12-23.

Twigg SM, Escalada J, Grisoni M-L, Stella P, Merino-Trigo A, Lavalle-Gonzalez FJ, Cariou B, Meneghini F. Age, BMI, and diabetes duration: effect on glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes (T2DM). 75th Scientific sessions of ADA, Boston, USA, 5-9 June 2015, Abstract 1017-P.

UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-1147.

Vague P, Selam JL, Skiele S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E. Insulin detemir is associated with more predicable glycemic control and reduced risk of hypoglycemia than NPH-insulin in patients with type 1 diabetes on basal-bolus regimen with premeal, insulin apart. Diabetes Care 2003;26:590-596 doi: 10.2337/diacare.26.3.590

Wood JR, Miller KM, Maahs DM, Beck RW, DiMeglio LA, Libman IM, Quinn M, Tamborlane WV, Woerner SE, T1D Exchange Clinic Network.Type 1 Diabetes exchange clinic registry do not meet American Diabetic Association or international Society for Pediatric and adolescent Diabete clinical guidelines. Diabetes Care 2013;36:2035-2037. doi: 10.2337/dc12-1959.

Workgroup on hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28:1245-1249. doi:10.2337/diacare.28.5.1245

Xie L, Wei W, Pan C, Baser O. Real-world rates, predictors and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. J Med Econ 2013;16:1137-1145. doi: 10.3111/13696998.2013.824458

Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation 2011;123:342-348. doi: 10.1161/CIRCULATIONAHA.110.948489.

Yale J-F, Aroda VR, Charbonnel B, Ritzel R, Merino-Trigo A, Stella P, Grisoni M-L, Sinclair AJ. Older people with type 2 diabetes: glycemic control and hypoglycemia risk with new insulin glargine 300 U/mL. 75th Scientific sessions of ADA, Boston, USA, 5-9 June 2015, Abstract 991-P.

Yki-Jarvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC, EDITION 2 Study Investigators. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37:3235-3243. doi:10.2337/dc14-0990.

Yki-Jarvinen H, Bergenstal RM, Bolli GB, Ziemen M, Wardecki M, Muehlen-Bartmer I, Maroccia M. Less nocturnal hypoglycemia and weight gain with new insulin glargine 300 U/ml compared with 100 U/ml: 1-year results in people with T2DM using basal insulin with OADs (EDITION 2). 74th Scientific sessions of ADA, San Francisco, USA, 13-17 June 2014, Abstract 93-LB.

Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301. doi: 10.1016/j.diabres.2010.01.026.

Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011;377:924-931. doi:10.1016/S0140-6736(10)62305-7.

Zongas S, Patel A, Chamers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Pascal Kengne A, M.D., Marre M, Heller S. for the ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-1418. doi:10.1056/NEJMoa1003795

Efimov AS, Poltorak VV. Autoimmunnyie aspektyi insulinzavisimogo saharnogo diabeta. Popyitki immunokorrektsii na rannih stadiyah zabolevaniya. Probl endokrinol 1989; 35:85-90.

Poltorak VV, Karachentsev YI, Gorshunska MY. Optymizatsiya hlikemichnoho kontrolyu u khvorykh na tsukrovyy diabet novymy analohamy insulinu (fiziolohichni modeli zamisnoyi insulinoterapiyi). Liky Ukrayiny 2005;91:63-68.

Poltorak VV, Krasova NS, Gorshunska MY. Glykemycheskaya pamyat' kak patohenetycheskoe osnovanye dlya formyrovanyya alhorytma sovremennoy antydyabetycheskoy terapyy. Mizhnarodnyy endokrynolohichnyy zhurnal 2014;(3):15-21.

Poltorak VV, Krasova NS, Gorshunskaia MY. Apoptoz pankreaticheskih beta-kletok kak novaya mishen dlya insulinoterapii bolnyih saharnyim diabetom 1 i 2 tipa. Problemyi endokrinnoy patologii 2015; 1:90-102.

Preparat Tozheo® (Toujeo®) zatverdzhenyy u Yevropeys'komu soyuzi dlya likuvannya diabetu u doroslykh – novyy bazal'nyy insulin pokazav hlikemichnyy kontrol' iz menshoyu kil'kistyu vypadkiv pidtverdzhenoyi hipohlikemiyi. Mizhnarodnyy endokrynolohichnyy zhurnal 2015; 67:96-98.

Tron'ko MD, Poltorak VV, Sokolova LK. Doslidzhennya ORIGIN (peredumovy, rezul'taty). Mizhnarodnyy endokrynolohichnyy zhurnal 2013; 49:15-22.

Tron'ko MD, Zak KP, Popova VV, Butenko AK. Saharnyiy diabet. Immunitet. Tsitokinyi. K.: Kniga-plyus. 2015, 488 p.

Chernobrovyy AD, Tron'ko MD. Dovidnyk osnovnykh pokaznykiv diyal'nosti endokrynolohichnoï sluzhby Ukraïny za 2013 rik. K. 2014, 40 p.




DOI: https://doi.org/10.22141/2224-0721.7.71.2015.72588

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru